Novo Nordisk Asks Fed. Circ. To Save Prandin Patent
Novo Nordisk A/S urged the Federal Circuit on Monday to reinstate a patent for its diabetes treatment Prandin, saying a lower court had ignored the U.S. Patent and Trademark Office's decision...To view the full article, register now.
Already a subscriber? Click here to view full article